Victoza (liraglutide) is approved primarily for type 2 diabetes , given as a once-daily injection, and it helps lower blood sugar by enhancing insulin release and slowing gastric emptying
This mandates that a successful BPC 157 effect (previously, without acting on gastric acid secretion (4-9), it healed the cysteamine pathology (29-33)), should be the synchronized healing of the different tissues, as shown with the healing of the gastrocutaneous, esophagocutaneous, and colocutaneous fistulas, also through the NO-system (10-12), and also interacting with NO-agents in different models and species (10, 12, 25, 34-40)
And we need to treat symptoms as they come
"Safe and affordable healthcare solutions for every individual should be the status quo." (Reporting by Amina Niasse in New York